NCE-1 Intelligence & Market Opportunity

Iomervu

Iomeprol

Diagnostic Agents

Intra-Arterial And Intravenous

Iomervu is an injectable contrast agent for CT scans and angiography in adults and children. It enhances artery and organ imaging by providing clear, safe visualization of vascular structures.

Approval Date

27-Nov-24

NCE-1 Date

27-Nov-28

NCE Date

27-Nov-29

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Iomeprol

Innovator

BRACCO DIAGNOSTICS INC

Dosage Form

Intra-Arterial And Intravenous

Strength

15 gm/50 mL, 17.5 gm/50 mL, 20 gm/50 mL, 25 gm/100 mL, 30 gm/100 mL, 35 gm/100 mL, 40 gm/100 mL, 60 gm/150 mL and 45 gm/150 mL

Therapeutic Category

Diagnostic Agents

Usage

For use as a radiographic contrast agent

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.